Luthra, Amarchand, Crawford, Shearman, Davis Polk advise on Sun Pharma’s $4 billion acquisition of Ranbaxy

Medicines

Indian drug maker, Sun Pharmaceutical Industries shall be paying about $4 billion in an all-stock deal to acquire generic drug maker Ranbaxy Laboratories. Daiichi Sankyo, the majority shareholder in Ranbaxy will acquire a 9 per cent stake in Sun Pharmaceutical after the deal.

Luthra & Luthra and Amarchand Mangaldas acted as the legal counsels for Ranbaxy. The Luthra team was led by Managing Partner Rajiv Luthra along with Partners Bobby Chandiok, Sameer Dudoria, Sandeep Dudeja, Damini Bhalla and Vaibhav Kakkar.

(2)

XYZ

April 7, 2014 - 11:27am

Brian Friedman is an associate and not a partner at Davis Polk. Please correct the information.

Your Name: 
XYZ

(2)

Rabbit

April 7, 2014 - 10:24am

Good going, Luthra! Well done!

Your Name: 
Rabbit

FEATURES
The Viewpoint - Recent Decisions on Schemes of Arrangement and Capital Reduction
Comments (0)
Wednesday, September 3, 2014 - 10:44am

Latest Tweets

Latest Tweets

Pickles & Lota: 11 September 2014
CONNECT

Follow us on